These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 34105315)
1. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study. Sørup S; Darvalics B; Russo L; Oksen D; Lamy FX; Verpillat P; Aa K; Ht S; Cronin-Fenton D Cancer Med; 2021 Jul; 10(14):4957-4963. PubMed ID: 34105315 [TBL] [Abstract][Full Text] [Related]
2. [Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer]. Jacquin-Porretaz C; Nardin C; Puzenat E; Roche-Kubler B; Aubin F; Presse Med; 2017 Sep; 46(9):808-817. PubMed ID: 28683958 [TBL] [Abstract][Full Text] [Related]
3. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195 [No Abstract] [Full Text] [Related]
4. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Atkins MB; Clark JI; Quinn DI Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639 [TBL] [Abstract][Full Text] [Related]
6. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285 [TBL] [Abstract][Full Text] [Related]
7. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153 [TBL] [Abstract][Full Text] [Related]
8. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059 [TBL] [Abstract][Full Text] [Related]
10. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647 [TBL] [Abstract][Full Text] [Related]
12. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830 [TBL] [Abstract][Full Text] [Related]
13. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Zhang H; Li X; Huang X; Li J; Ma H; Zeng R J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497 [TBL] [Abstract][Full Text] [Related]
14. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868 [TBL] [Abstract][Full Text] [Related]
15. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Krieger T; Pearson I; Bell J; Doherty J; Robbins P Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815 [TBL] [Abstract][Full Text] [Related]
16. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774 [TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. Hwang I; Park I; Yoon SK; Lee JL Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433 [TBL] [Abstract][Full Text] [Related]
19. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087 [TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]